Tibotec-Virco Overview

  • Founded
  • 2001
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 2
  • Investments
  • 2

Tibotec-Virco General Information

Description

Operator of a biotechnology company. The company develops drugs and technologies for the treatment of HIV/AIDS. The company also focuses on development of treatments for cancer, hepatitis C and other infectious diseases.

Contact Information

Website
www.tibotec.com
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • Gen De Wittelaan L 11B 3
  • 2800 Mechelen
  • Belgium
+32 015 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tibotec-Virco Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tibotec-Virco‘s full profile, request access.

Request a free trial

Tibotec-Virco Executive Team (3)

Name Title Board Seat Contact Info
Philippe Ballero Chief Executive Officer
You’re viewing 1 of 3 executive team members. Get the full list »

Tibotec-Virco Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tibotec-Virco‘s full profile, request access.

Request a free trial

Tibotec-Virco Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 14-Mar-2001 000000 00 000000 Diagnostic Equipment
Galapagos (Belgium) 01-Jan-1999 Joint Venture Biotechnology
To view Tibotec-Virco’s complete investments and acquisitions history, request access »

Tibotec-Virco Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 (0000000 01-Jan-1999 00000 0000000 Completed
  • 2 buyers
To view Tibotec-Virco’s complete exits history, request access »